Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

GLEOLAN

×

Overview

What is GLEOLAN?



What does GLEOLAN look like?



What are the available doses of GLEOLAN?

For oral solution: 1,500 mg ALA HCl lyophilized powder, equivalent to 1,170 mg ALA per vial. The reconstituted ALA HCl solution contains 30 mg per mL and is clear and colorless to slightly yellowish in color.

What should I talk to my health care provider before I take GLEOLAN?

How should I use GLEOLAN?

Gleolan is indicated in patients with glioma [suspected World Health Organization (WHO) Grades III or IV on preoperative imaging] as an adjunct for the visualization of malignant tissue during surgery.

For oral use only

Recommended reconstituted oral dose of Gleolan is 20 mg/kg. ()

Administer Gleolan to patient orally 3 hours (range 2 to 4 hours) before anesthesia. ()

See Full Prescribing Information for reconstitution information. ()

Use appropriate visualization techniques with appropriate surgical microscopes and light source filters. ()


What interacts with GLEOLAN?

Sorry No Records found


What are the warnings of GLEOLAN?

Sorry No Records found


What are the precautions of GLEOLAN?

Sorry No Records found


What are the side effects of GLEOLAN?

Sorry No records found


What should I look out for while using GLEOLAN?

Hypersensitivity to ALA or porphyrins. (, , )

Acute or chronic types of porphyria. ()


What might happen if I take too much GLEOLAN?

Overdosage has been associated with respiratory insufficiency and erythema. In the event of overdose, supportive measures should be provided as necessary, including protection from strong light sources.


How should I store and handle GLEOLAN?

Store at 25 °C (77 °F); excursions permitted to 15-30 °C (59-86 °F). Product: 63629-1335NDC: 63629-1335-1 10 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-2 30 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-3 20 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-4 60 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-5 4 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-6 5 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-7 100 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-8 6 TABLET, FILM COATED in a BOTTLEProduct: 63629-1335NDC: 63629-1335-1 10 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-2 30 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-3 20 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-4 60 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-5 4 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-6 5 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-7 100 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-8 6 TABLET, FILM COATED in a BOTTLEProduct: 63629-1335NDC: 63629-1335-1 10 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-2 30 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-3 20 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-4 60 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-5 4 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-6 5 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-7 100 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-8 6 TABLET, FILM COATED in a BOTTLEProduct: 63629-1335NDC: 63629-1335-1 10 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-2 30 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-3 20 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-4 60 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-5 4 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-6 5 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-7 100 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-8 6 TABLET, FILM COATED in a BOTTLEProduct: 63629-1335NDC: 63629-1335-1 10 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-2 30 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-3 20 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-4 60 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-5 4 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-6 5 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-7 100 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-8 6 TABLET, FILM COATED in a BOTTLEProduct: 63629-1335NDC: 63629-1335-1 10 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-2 30 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-3 20 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-4 60 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-5 4 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-6 5 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-7 100 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-8 6 TABLET, FILM COATED in a BOTTLEProduct: 63629-1335NDC: 63629-1335-1 10 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-2 30 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-3 20 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-4 60 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-5 4 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-6 5 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-7 100 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-8 6 TABLET, FILM COATED in a BOTTLEProduct: 63629-1335NDC: 63629-1335-1 10 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-2 30 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-3 20 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-4 60 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-5 4 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-6 5 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-7 100 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-8 6 TABLET, FILM COATED in a BOTTLEProduct: 63629-1335NDC: 63629-1335-1 10 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-2 30 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-3 20 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-4 60 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-5 4 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-6 5 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-7 100 TABLET, FILM COATED in a BOTTLENDC: 63629-1335-8 6 TABLET, FILM COATED in a BOTTLE


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

ALA occurs endogenously as a metabolite that is formed in the mitochondria from succinyl-CoA and glycine. Exogenous administration of ALA leads to accumulation of the ALA metabolite PpIX in tumor cells. The reason for the accumulation of PpIX in neoplastic brain tissue is not known.

During glioma surgery, Gleolan is used with an operating microscope adapted with a blue emitting light source (power density 40-80 mW/cm) and filters for excitation light of wavelength 375 to 440 nm, and observation at wavelengths of 620 to 710 nm. This allows tumor tissue to be visualized as red fluorescence. Tissue lacking sufficient PpIX concentrations appears blue.

Non-Clinical Toxicology
Hypersensitivity to ALA or porphyrins. (, , )

Acute or chronic types of porphyria. ()

Antipsychotic drugs such as phenothiazines or haloperidol; tricyclic antidepressants .

Due to the risk of phototoxic reactions, do not administer phototoxic drugs for 24 hours during the perioperative period . Reduce exposure to sunlight or room lights for 48 hours after administration of Gleolan.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).